Similar articles

Abstract: It is of great importance to investigate an effective and reliable medication against chronic renal failure (CRF)-related erectile dysfunction (ED), which aims to improve patients’ life qualities. The concentrations of cyclic guanosine monophosphate (cGMP) in the corpus cavernosal smooth muscle of both CRF and control rabbits were measured. The effects of various concentrations of tadalafil, papaverine, and sodium nitroprusside on the relaxation responses of corpus cavernosal smooth muscle pre-contracted with phenylephrine in CRF rabbits were observed. There was significant difference in the concentration of cGMP between CRF and control rabbits (P<0.01). tadalafil had the greatest impacts on CRF rabbits when given the same concentration of papaverine or sodium nitroprusside and particularly significant differences were identified under the concentration levels of 10⁻⁵ and 10⁻⁴ mol/L (P<0.01). The results suggest that the cGMP concentrations of the corpus cavernosum had been greatly reduced in CRF rabbits compared with control rabbits and that tadalafil may be an ideal medication for use in the treatment of CRF-related ED.

[1]Ahn, T.Y., Lee, S.W., Kim, S.W., Yang, D.Y., Park, N.C., Min, K.S., Park, K., Paick, J.S., Dyachkova, Y., Dwight, T., et al., 2007. Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil. Asian J. Androl., 9(6):760-770.

[2]Bagcivan, I., Kilicarslan, H., Sarac, B., Gokce, G., Yildirim, S., Ayan, S., Sarioglu, Y., 2003. The evaluation of the effects of renal failure on erectile dysfunction in a rabbit model of chronic renal failure. BJU Int., 91(7):697-701.

[3]Barrou, B., Cuzin, B., Malavaud, B., Petit, J., Pariente, J.L., Buchler, M., Cormier, L., Benoit, G., Costa, P., 2003. Early experience with sildenafil for the treatment of erectile dysfunction in renal transplant recipients. Nephrol. Dial. Transplant., 18(2):411-417.

[4]Brock, G.B., McMahon, C.G., Chen, K.K., Costigan, T., Shen, W., Watkins, V., Anglin, G., Whitaker, S., 2002. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J. Urol., 168(1):1332-1336.

[5]Burnett, A.L., 2008. Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health. J. Androl., 29(1):3-14.

[6]Chen, J., Mabjeesh, N.J., Greenstein, A., Nadu, A., Matzkin, H., 2001. Clinical efficacy of sildenafil in patients on chronic dialysis. J. Urol., 165(3):819-821.

[7]Eardley, I., Gentile, V., Austoni, E., Hackett, G., Lembo, D., Wang, C., Beardsworth, A., 2004. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction. BJU Int., 94(6):871-877.

[8]Frajese, G.V., Pozzi, F., Frajese, G., 2006. Tadalafil in the treatment of erectile dysfunction: an overview of the clinical evidence. Clin. Interv. Aging, 1(4):439-449.

[9]Fu, Q., Yao, D.H., Jiang, Y.Q., 2000. A clinical comparative study on effects of intracavernous injection of sodium nitroprusside and papaverine/phentolamine in erectile dysfunction patients. Asian J. Androl., 2(4):301-313.

[10]Gratzke, C., Uckert, S., Kedia, G., Reich, O., Schlenker, B., Seitz, M., Becker, A.J., Stief, C.G., 2007. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Urol. Res., 35(1):49-54.

[11]Khan, M.A., Thompson, C.S., Jeremy, J.Y., Mumtaz, F.H., Mikhailidis, P., Morgan, R.J., 2001. The effect of superoxide dismutase on nitric oxide-mediated and electrical field-stimulated diabetic rabbit cavernosal smooth muscle relaxation. BJU Int., 87(1):98-103.

[12]Kilicarslan, H., Yildirim, S., Bagcivan, I., Ayan, S., Sarac, B., Sarioglu, Y., 2002. Effect of chronic renal failure on the purinergic responses of corpus cavernosal smooth muscle in rabbits. BJU Int., 90(6):596-600.

[13]Kilicarslan, H., Yildirim, S., Bagcivan, I., Gokce, G., Sarac, B., Sarioglu, Y., 2003. The effect of chronic renal failure on phosphodiesterase inhibitor-induced relaxation responses in rabbit cavernosal strips. Eur. J. Pharmacol., 462(6):155-160.

[14]McCullough, A.R., Steidle, C.P., Klee, B., Tseng, L.J., 2008. Randomized, double-blind, crossover trial of sildenafil in men with mild to moderate erectile dysfunction: efficacy at 8 and 12 hours postdose. Urology, 71(4):686-692.

[15]Mirone, V., Imbimbo, C., Rossi, A., Sicuteri, R., Valle, D., Longo, N., Fusco, F., 2007. Evaluation of an alternative dosing regimen with tadalafil, three times per week, for men with erectile dysfunction: SURE study in Italy. Asian J. Androl., 9(3):395-402.

[16]Moncada, S., Palmer, R.M., Higgs, E.A., 1991. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev., 43(2):109-142.

[17]Montani, D., Chaumais, M.C., Savale, L., Natali, D., Price, L.C., Jaïs, X., Humbert, M., Simonneau, G., Sitbon, O., 2009. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv. Ther., 26(9):813-825.

[18]Nassir, A., 2009. Sexual function in male patients undergoing treatment for renal failure: a prospective view. J. Sex. Med., 6(12):3407-3414.

[19]Neto, A.F., de Freitas Rodrigues, M.A., Saraiva Fittipaldi, J.A., Moreira, E.D.Jr., 2002. The epidemiology of erectile dysfunction and its correlates in men with chronic renal failure on hemodialysis in Londrina, southern Brazil. Int. J. Impot. Res., 14(Suppl. 2):19-26.

[20]Shamloul, R., Atteya, A., Elnashaar, A., Gadallah, A., Zohdy, W., Abdelsalam, W., 2005. Intracavernous sodium nitroprusside (SNP) versus papaverine/phentolamine in erectile dysfunction: a comparative study of short-term efficacy and side-effects. J. Sex. Med., 2(1):117-120.

[21]Yip, W.C., Chiang, H.S., Mendoza, J.B., Tan, H.M., Li, M.K., Wang, W.C., Kopernicky, V., 2006. Efficacy and safety of on demand tadalafil in the treatment of East and Southeast Asian men with erectile dysfunction: a randomized double-blind, parallel, placebo-controlled clinical study. Asian J. Androl., 8(6):685-692.